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Abstract: STUDY OBJECTIVES: Obstructive sleep apnea (OSA) promotes myocardial electrical insta-
bility and may predispose to nocturnal sudden cardiac death. We evaluated whether hypobaric hypoxia
during altitude travel further impairs cardiac repolarization in patients with OSA, and whether this is
prevented by acetazolamide, a drug known to improve oxygenation and central sleep apnea at altitude.
METHODS: Thirty-nine OSA patients living < 600 m, discontinued continuous positive airway pressure
therapy during studies at 490 m and during two sojourns of 3 days at altitude (2 days at 1860 m, 1 day
at 2590 m). During one altitude sojourn, patients took acetazolamide, during the other placebo, or vice
versa, according to a randomized, double-blind crossover design. Twelve-lead electrocardiography and
pulse oximetry (SpO2) were recorded during nocturnal polysomnography. Heart rate corrected mean QT
intervals during the entire night (meanQTc) and during 1 min of the night with the longest meanQTc
(maxQTc) were determined. RESULTS: At 490 m the median nocturnal SpO2 was 93%, medians of
meanQTc and maxQTc were 420 ms and 478 ms. At 2590 m, on placebo, SpO2 was lower (85%), and
meanQTc and maxQTc were prolonged to 430 ms and 510 ms (P < 0.02 vs. 490 m, all corresponding
comparisons). At 2590 m on acetazolamide, median SpO2 was increased to 88% (P < 0.05 vs. placebo),
meanQTc was reduced to 427 ms (P < 0.05 vs. placebo), whereas maxQTc remained increased at 502
ms (P = ns vs. placebo). CONCLUSIONS: At 2590 m OSA patients experienced cardiac repolarization
disturbances in association with hypoxemia. Prolongation of meanQTc at altitude was prevented and
hypoxemia was improved by acetazolamide, whereas maxQTc remained increased suggesting imperfect
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Study Objectives: Obstructive sleep apnea (OSA) promotes myocardial electrical instability and may predispose to nocturnal sudden cardiac death. We 
evaluated whether hypobaric hypoxia during altitude travel further impairs cardiac repolarization in patients with OSA, and whether this is prevented by 
acetazolamide, a drug known to improve oxygenation and central sleep apnea at altitude.
Methods: Thirty-nine OSA patients living < 600 m, discontinued continuous positive airway pressure therapy during studies at 490 m and during two 
sojourns of 3 days at altitude (2 days at 1860 m, 1 day at 2590 m). During one altitude sojourn, patients took acetazolamide, during the other placebo, or 
vice versa, according to a randomized, double-blind crossover design. Twelve-lead electrocardiography and pulse oximetry (SpO2) were recorded during 
nocturnal polysomnography. Heart rate corrected mean QT intervals during the entire night (meanQTc) and during 1 min of the night with the longest 
meanQTc (maxQTc) were determined.
Results: At 490 m the median nocturnal SpO2 was 93%, medians of meanQTc and maxQTc were 420 ms and 478 ms. At 2590 m, on placebo, SpO2 
was lower (85%), and meanQTc and maxQTc were prolonged to 430 ms and 510 ms (P < 0.02 vs. 490 m, all corresponding comparisons). At 2590 m on 
acetazolamide, median SpO2 was increased to 88% (P < 0.05 vs. placebo), meanQTc was reduced to 427 ms (P < 0.05 vs. placebo), whereas maxQTc 
remained increased at 502 ms (P = ns vs. placebo).
Conclusions: At 2590 m OSA patients experienced cardiac repolarization disturbances in association with hypoxemia. Prolongation of meanQTc at altitude 
was prevented and hypoxemia was improved by acetazolamide, whereas maxQTc remained increased suggesting imperfect protection from repolarization 
disturbances.
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INTRODUCTION
Obstructive sleep apnea (OSA) is a highly prevalent sleep-related 
breathing disorder with prevalence rates of 5% to 19 % of the 
adult population in Western countries.1–3 OSA is characterized by 
repetitive interruption of airflow through the pharyngeal airway 
during sleep, leading to oxygen desaturations, fragmented sleep, 
and excessive daytime sleepiness. Patients with OSA are at in-
creased risk of hypertension and vascular dysfunction4–7 and 
there is evidence that OSA is associated with cardiac arrhyth-
mias and sudden cardiac death, especially in the early morning 
hours.8–12 Approximately 50% of patients with symptomatic OSA 
have cardiac arrhythmias during sleep, mostly associated with 
an episode of obstructive apnea.13 Intermittent hypoxia caused by 
OSA is assumed to promote cardiac arrhythmias by producing 
oxidative stress, systemic inflammation, and increased sympa-
thetic activity.6 Withdrawal of continuous positive airway pres-
sure (CPAP) in patients with OSA7 and simulated obstructive 
apnea in healthy subjects14 are associated with QTc prolongation, 
pii: sp-00043-16 ht tp://dx.doi.org/10.5665/sleep.6080
Significance
Obstructive sleep apnea (OSA) is a highly prevalent disorder associated with considerable cardiovascular morbidity and mortality. The current 
randomized placebo-controlled trial demonstrates that patients with OSA who discontinued continuous positive airway pressure (CPAP) therapy during 
a stay at moderate altitude suffer from disturbed cardiac repolarization with a prolongation of the QTc interval and greater dispersion, suggesting an 
increase in the risk of malignant arrhythmias. Because acetazolamide prevents prolongation of the mean QTc interval, the drug might be beneficial for 
OSA patients who are unable to use CPAP therapy during altitude travel. The results are important because they might have an effect on the clinical 
practice and because the study provides novel insights into the pathophysiology of cardiac repolarisation and control of breathing.
suggesting that the cardiac arrhythmia in OSA patients may be 
mediated by disturbances of cardiac repolarization.8
Many patients with OSA travel to altitude for professional 
or recreational activities. We have previously shown that al-
titude exposure aggravates nocturnal hypoxemia and exacer-
bates sleep apnea in OSA patients, and may therefore further 
increase the risk of cardiac repolarization disturbances and ar-
rhythmia.15 Although nocturnal CPAP therapy may improve 
oxygen saturation and sleep apnea, many OSA patients prefer 
to discontinue this treatment during altitude travel because car-
rying a CPAP device is inconvenient and electrical power is not 
always available. Acetazolamide therapy in combination with 
CPAP, or as the sole treatment if CPAP is not feasible, confers 
some benefit to OSA patients during altitude travel because it 
improves nocturnal oxygen saturation, sleep apnea, and subjec-
tive sleep quality.16,17 However, whether acetazolamide therapy 
may reduce or prevent disturbances of cardiac repolarization 
and arrhythmias in OSA patients staying at altitude has not 
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been studied. Therefore, the purpose of the current study was 
to perform a randomized, placebo-controlled trial evaluating 
the hypotheses that (1) cardiac repolarization as reflected by a 
prolonged QTc interval is disturbed in OSA patients during a 
stay at altitude, and (2) that the altitude-induced QTc prolonga-
tion is prevented by acetazolamide therapy.
METHODS
Study Design
This randomized, placebo-controlled, double-blind crossover 
trial evaluated the effects of a 3-day altitude sojourn on indices 
of cardiac repolarization in OSA patients discontinuing their 
long-term CPAP therapy; in addition, the efficacy of acetazol-
amide in preventing the effects of altitude on cardiac repolar-
ization was tested. As described in detail previously,16 the trial 
included two altitude sojourns of 3 days each, one with acetazol-
amide, the other with placebo treatment, or vice versa, according 
to a randomized crossover design, separated by a 2-w washout 
period at < 600m (see next section). The study was approved by 
the institutional ethics committee, registered at clinicaltrials.gov 
NCT00714740, and all patients gave written informed consent. 
The primary outcomes of the trial (apnea-hypopnea index and 
nocturnal oxygen saturation) are reported in detail elsewhere,16 
and the data on cardiac repolarization, the focus of the current 
report, have not been published previously.
Setting and Participants
Baseline studies were carried out at the University Hospital in 
Zurich, Switzerland (490 m, barometric pressure 717 mmHg), 
altitude measurements were performed in the Swiss moun-
tain resorts Davos Schatzalp (1860 m, barometric pressure 607 
mmHg) and Davos Jakobshorn (2590 m, barometric pressure 
554 mmHg). We invited OSA patients of both sexes, age 20 to 
80 y, on successful CPAP therapy for more than 3 mo and living 
at an altitude below 600 m, to participate in our study. The diag-
nosis of OSA was based on an elevated apnea-hypopnea index 
(AHI) and symptoms of excessive daytime sleepiness docu-
mented in the medical records, prior to the start of CPAP therapy. 
Study inclusion required more than 15 oxygen desaturations per 
hour (> 3% SpO2 dips) during a current ambulatory pulse oxim-
etry performed at the end of a 4-night period without CPAP in 
Zurich. In addition, polysomnography at 490 m had to show an 
AHI > 10 events/h with predominant obstructive events.
Randomization and Interventions
Participants were randomized to one of four sequences of al-
titude exposure and to two sequences of drug treatment ac-
cording to a nested, balanced block design, i.e., they spent 
1 day/night each at the following altitudes:
• sequence A: 490, 1860, 1860, 2590 m – 2 w low 
altitude washout – 1860, 1860, 2590 m; 
• sequence B: 490, 1860, 2590, 1860 m – 2 w low 
altitude washout – 1860, 2590, 1860 m; 
• sequence C: 1860, 1860, 2590 m – 2 w low altitude 
washout – 1860, 1860, 2590, 490 m; 
• sequence D: 1860, 2590, 1860 m – 2 w low altitude 
washout – 1860, 2590, 1860, 490 m.16 
During the first altitude sojourn patients took acetazolamide 
and during the second sojourn placebo, or vice-versa, ac-
cording to randomization. Polysomnography and 12-lead 
electrocardiography (ECG) monitoring were assessed in the 
night at 490 m, in the second night at 1860 m and in the night 
at 2590 m. Patients chose among available study time slots 
without being aware of the order of altitude exposure assigned 
to them. The order of treatment with acetazolamide (2 × 250 
mg/d) and placebo during the two altitude sojourns was ran-
domized by letting participants select a medication set from a 
box containing several identically looking sets of study drugs. 
Patients and investigators were blinded to the study treatment 
until completion of data analysis.
Assessments
Participants were monitored with a 12-lead surface Holter 
ECG device during time in bed (Getemed, CardioDay ECG 
analyses software V2.2.0).18,19 According to international stan-
dards,20 the device recorded all leads simultaneously during 
the entire night, identified the lead with the longest QT inter-
vals and averaged the values every five heartbeats. The QT in-
tervals automatically determined by the software in this way 
was validated visually.
The corrected QT interval was calculated by the Bazett for-
mula (QTc = QT interval divided by the square root of the RR 
interval).21,22 Mean values of QTc computed for the entire night 
(meanQTc), and mean QTc computed for the minute of the 
night with highest (maxQTc) and lowest values (minQTc) and 
the difference between these (max-minQTc) as a measure of 
variability were determined. QT dispersion among the simul-
taneously recorded 12 leads was computed as the difference in 
QT interval in the lead with the longest QT interval minus the 
corresponding value in the lead with the shortest QT interval.20 
This analysis was performed for periods in the early morning 
(05:00–06:00) when the longest QT intervals were expected. 
Supraventricular and ventricular arrhythmias and bradycardia 
events (heart rate < 50/min for > 4 beats) were scored. Poly-
somnographic sleep studies comprised standard neurophysi-
ologic measurements,17,23 calibrated respiratory inductance 
plethysmography,24 diaphragmatic surface electromyography 
to differentiate obstructive from central apneas/hypopneas, 
transcutaneous PCO2 (PtcCO2)25 , airflow and pulse oximetry. 
Morning examinations included measurements of blood pres-
sure, pulse oximetry and body weight.
Outcomes
The main outcome of the current analysis was the QTc interval 
duration. Secondary outcomes included the number of noc-
turnal arrhythmia events, heart rate, arterial oxygen saturation 
by pulse oximetry and the AHI. A sample size estimation per-
formed in relation to the primary outcomes of the main study 
(AHI and the mean nocturnal oxygen saturation) suggested 
that at least 44 patients should be randomized.16
Statistical Analysis
As most variables were not normally distributed, data are sum-
marized as medians and quartiles. Analyses of drug effects 
were conducted on an intention-to-treat principle with missing 
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values substituted by corresponding values on 
the alternative drug assuming no effect of ac-
etazolamide. Effects of altitude and acetazol-
amide were evaluated by Friedman analysis 
of variance followed by post hoc analysis with 
Wilcoxon matched pairs tests as appropriate. 
Effects of interventions (altitude exposure, ac-
etazolamide therapy) were further quantified 
by median differences with 95 % confidence 
intervals.17 Multivariable, random-effects, gen-
eralized least-square regression models were 
adapted to the mean QTc interval (which was 
normally distributed) to assess the effects of 
treatment when controlling for potential con-
founders including time of the night spent with 
oxygen saturation < 90% as a measure of sus-
tained hypoxia at altitude, AHI, age, and sex. 
Two-sided tests applying a Bonferroni correc-
tion were applied and P < 0.05 was considered 
statistically significant.17
RESULTS
Of 75 screened patients, 49 met inclusion cri-
teria and were randomized (Figure 1). One 
patient withdrew from the study after the first 
night at 2590 m because of an acute peripheral 
vestibulopathy. Data from three patients had 
to be excluded according to the predefined cri-
teria, because polysomnography at 490 m re-
vealed an obstructive AHI < 10 events/h in two 
patients and predominant central sleep apnea 
in one patient.16 Five had to be excluded be-
cause of atrial fibrillation and one because of a 
pacemaker rhythm that prevented reliable QTc 
measurement. Table 1 shows the characteris-
tics of the 39 participants (36 men, 3 women) 
included into the analyses.
Results of ECG recordings and polysomnography are sum-
marized in Tables 1, 2, and 3 and Figures 2 and 3. Baseline 
studies without CPAP at 490 m revealed median values of 
meanQTc of 420 ms, maxQTc of 478 ms, max-minQTc (QTc 
variability) of 82 ms and QT dispersion of 35 ms, which lies 
in the normal range for both men and women.26 At 1860 m 
and 2590 m on placebo the QTc intervals were significantly 
prolonged (meanQTc 436 ms and 430 ms; maxQTc 499 ms 
and 510 ms, respectively) compared to corresponding values 
at 490 m (Table 2, Figure 2). Moreover, the measures of QT 
variability (max-minQTc) and of QT dispersion were also sig-
nificantly larger at 2590 m than at 490 m (Table 2). On acet-
azolamide at 1860 m and 2590 m, meanQTc were significantly 
shorter (422 ms and 427 ms) than on placebo at corresponding 
altitude, and similar to the values at 490m, while maxQTc 
remained prolonged (494 ms and 502 ms). Acetazolamide de-
creased the meanQTc by −6 ms (95% CI, −2 ms to −12 ms) 
at 1860 m and by −10 ms (95% confidence interval [CI], 0 to 
−12 ms) at 2590 m and it decreased QT dispersion by −12 ms 
(95% CI, −6 ms to −22 ms) at 1860 m and by −25 ms (95% CI, 
−21 to −37 ms) at 2590 m (Figure 3).
Table 1—Characteristics of patients.
Demographics and clinical characteristics
n 39 (36 m, 3 f)
Age, y, median (quartiles) 64 (58;66)
BMI, kg/m2, median (quartiles) 31.2 (26.5;35.8)
Comorbidities, n (%)
Arterial hypertension 27 (69)
Stable coronary artery disease 4 (10)





Calcium channel blocker 3 (8)
β-blocker 9 (23)
ACE-inhibitor/angiotensin II receptor blockers 18 (46 )
Glucose lowering medication 4 (10)
Lipid lowering therapy 10 (26)
ACE, angiotensin-converting enzyme; BMI, body mass index.
Figure 1—Patient flow. AHI, apnea-hypopnea index; b/o, because of; CPAP, continuous 
positive airway pressure; CSA, predominant central sleep apnea; ODI, oxygen desaturation 
index.
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Multivariable, random-effects, generalized least-square re-
gression analysis was performed with the mean QTc interval as 
the dependent variable and percent time spent with oxygen sat-
uration below 90%, acetazolamide/placebo therapy, AHI, age, 
and sex as independent variables (Table 3). This analysis con-
firmed independent effects of acetazolamide and of hypoxemia.
There were fewer bradycardia events on acetazolamide at 
2590 m compared to placebo. The number of supraventricular 
and ventricular arrhythmias was not significantly influenced 
by altitude or treatment. Mean nocturnal heart rate was in-
creased at 2590 m on placebo and acetazolamide.
DISCUSSION
We studied measures of cardiac repolarization and arrhythmias 
in patients with OSA who discontinued their CPAP therapy 
during altitude travel. The nocturnal recordings revealed that 
ascending from 490 m to 2590 m induced considerable pro-
longations of the mean and maximal QTc intervals (median 
increase in meanQTc +8 ms, in maxQTc +38 ms), and an in-
crease of the QT dispersion (median increase +28 ms). In 24 
of 38 patients (63%) staying 1 night at 2590 m (on placebo) the 
maxQTc reached very high values exceeding 500 ms. Because 
prolongation and increased dispersion of cardiac repolariza-
tion have been associated with malignant cardiac arrhythmia 
and sudden cardiac death9–12,20,27,28 our data suggest that un-
treated OSA patients are at increased risk of such adverse car-
diac events when traveling to altitude without treatment. The 
current randomized, placebo-controlled trial further demon-
strates that acetazolamide prevented the altitude-induced pro-
longation of meanQTc and of QT dispersion in OSA patients 
and may therefore provide some benefit if CPAP is not feasible.
Intermittent hypoxia is a physiological consequence of 
OSA that promotes cardiac arrhythmias by autonomic ner-
vous system activation, increased oxidative stress and altered 
myocardial excitability.5 Recurrent arousals following the re-
spiratory events lead to sympathetic activation and possibly 
coronary vasoconstriction. Furthermore, increased nega-
tive intrathoracic pressure swings during obstructive apnea/
hypopnea may stretch the myocardial wall and intrathoracic 
vessels. These mechanical effects could enforce changes in 
myocardial excitability and may also lead to structural remod-
eling of the myocardium.6 Disturbances of cardiac repolariza-
tion have been reported in OSA patients based on prolonged 
and variable QT intervals that suggested myocardial electrical 
Table 2—Results of electrocardiography monitoring and polysomnography (n = 39).
Zurich 490 m
Davos Schatzalp 1860 m Davos Jakobshorn 2590 m
PPlacebo Acetazolamide Placebo Acetazolamide
meanQTc, ms 420 (416;440) 436 (420;453) c 422 (410;440) a 430 (420;450) c 427 (410;442) a < 0.001
maxQTc, ms 478 (458;510) 499 (477;536) c 494 (465;522) c 510 (483;553) c 502 (478;538) c < 0.001
max-minQTc, ms 82 (55;172) 134 (77;170) 131 (84;278) 130 (105;216) c 134 (97;236) c 0.002
QT dispersion, ms 35 (27;45) 51 (40;70) c 32 (25;48) a 64 (46;73) c 29 (25;44) a < 0.001
Supraventricular arrhythmias, 1/h 2.13 (0.68;3.86) 2.14 (1.26;4.71) 1.17 (0.38;3.87) 1.79 (0.47;4.91) 1.53 (0.41;3.53) 0.003
Ventricular arrhythmias, 1/h 0.80 (0.00;7.95) 0.58 (0.12;9.29) 0.59 (0.00;7.83) 0.48 (0.00;8.51) 0.33 (0.11;12.41) 0.526
Bradycardia events, 1/h 0.0 (0.0;2.7) 0.1 (0.0;14.3) 0.0 (0.0;0.5) 0.5 (0.0;14.4) 0.0 (0.0;0.3) a < 0.001
Heart rate, 1/min 64 (57;72) 66 (60;74) 68 (60;75) c 68 (60;73) c 69 (61;74) c 0.012
Mean arterial blood pressure, mmHg 104 (96;115) 103 (95;112) 98 (94;110) a,c 108 (101;114) 101 (97;108) 0.008
% time with oxygen saturation < 90% 9.6 (3.5;27.7) 50.9 (30.4;59.7) c 21.4 (10.5;43.3) a,c 75.9 (63.8; 88.8) b,c 57.8 (41.1;78.1) a,b,c < 0.001
Mean oxygen saturation, % 93 (92;94) 89 (88;90) c 91 (89;93) a,c 85 (83;88) b,c 88 (85;89) a,b,c < 0.001
Apnea-hypopnea index, total, 1/h 50.9 (41.4;73.1) 63.6 (47.9;87.4) c 49.1 (26.0;62.4) a 86.2 (65.9;105.8) b,c 57.8 (49.2;83.8) a,b,c < 0.001
Values presented as medians (quartiles). P values are listed for Friedman analysis of variance. Results of Wilcoxon matched pairs tests applying Bonferroni 
correction: a P < 0.05 vs. placebo at same altitude. b P < 0.05 vs. 1860 m within treatment. c P < 0.05 vs. 490 m. Mean QTc intervals were computed for the 
entire night (meanQTc), for the minute of the night with highest (maxQTc) and lowest values (minQTc). The differences (max-minQTc) and QT dispersion 
were computed as measures of QT variability and dispersion, respectively.
Table 3—Regression analysis of the effect of altitude and acetazolamide on the mean QTc interval (dependent variable).
Independent Variables
Univariable Analysis Multivariable Analysis
Coefficient 95% CI P Coefficient 95% CI P
% time with oxygen saturation < 90% 0.109 0.023 to 0.195 0.014 0.111 0.031 to 0.191 0.007
Drug effect, acetazolamide vs. placebo −4.76 −8.03 to −1.48 0.004 −6.32 −11.85 to −0.78 0.025
Apnea-hypopnea index, 1/h 0.105 0.034 to 0.175 0.004 −0.060 −0.161 to 0.041 0.245
Age, per year older 0.27 −0.34 to 0.88 0.392 0.06 −0.60 to 0.72 0.849
Sex, female vs. male 28.3 12.7 to 44.0 < 0.001 27.8 12.1 to 43.4 < 0.001
n = 156 observations at 1860 m and 2590 m (39 participants). Mean QTc interval was the dependent variable. Placebo was encoded as 1, acetazolamide 
as 2; male sex was encoded as 1 and female as 2. CI, confidence interval.
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instability.11,12,29,30 Gillis et al. 31 observed a significant prolon-
gation of QTc and decreasing heart rate during severe apneas 
as well as shortening of QTc and abrupt increases in the heart 
rate during the post apneic hyperventilation period. These 
sudden changes in cardiac repolarization and heart rate may 
be significant triggers in the development of ventricular ar-
rhythmias and may contribute to the cardiovascular mortality 
of OSA in particular during the night.8,31
We have previously shown that untreated OSA patients trav-
eling to altitude experience pronounced hypoxemia and an 
exacerbation of sleep apnea due to frequent central events.15 
This was associated with an increase in the incidence of ven-
tricular extra beats, suggesting that aggravation of intermittent 
and sustained hypoxia promoted cardiac electrical instability. 
Rossi et al.7 demonstrated in OSA patients on long-term CPAP 
therapy that withdrawal of the treatment for 2 w was associ-
ated with a prolongation of QTc measured during daytime. 
The amount of QTc prolongation was correlated with the se-
verity of the recurring sleep apnea. The findings of the current 
trial corroborate and extend these findings by suggesting that 
the exposure to hypobaric hypoxia during a stay at altitude 
without CPAP therapy represents an even greater risk of ma-
lignant cardiac arrhythmia and sudden cardiac death for OSA 
patients compared to discontinuation of CPAP in normobaric 
conditions near sea level.9,10,27,28,32,33 Regression analysis re-
vealed that the QTc prolongation observed at higher altitude 
was related to the greater degree of hypoxemia rather than to 
the increase in central apneas (Table 3). In the current study, 
the incidence of ventricular arrhythmias at 490 m was low and 
it was not significantly increased at the higher altitudes despite 
the prolongation of QTc. This may have been related to an in-
sufficient sample size and to the fact that only 4 of the 39 pa-
tients in the current study had (stable) coronary heart disease 
that predisposes to arrhythmia34 during exposure to hypoxia.
Acetazolamide has been shown to prevent acute moun-
tain sickness and reduce high altitude periodic breathing in 
healthy subjects.35,36 This carbonic anhydrase inhibitor stimu-
lates ventilation and improves oxygenation by promoting renal 
elimination of bicarbonate thereby counteracting the altitude 
induced respiratory alkalosis. In patients with OSA at low alti-
tude, acetazolamide has no clinically relevant effect on sleep-
related breathing disturbances. However, in OSA patients 
traveling to altitude and on acetazolamide, we have shown 
Figure 2—QTc intervals in patients with obstructive sleep apnea at three 
different altitudes during discontinuation of continuous positive airway 
pressure therapy. White boxes with whiskers and dots represent medians, 
quartiles, 5th, 10th, 90th and 95th percentiles during placebo treatment, 
gray boxes represent corresponding values during acetazolamide 
treatment. Mean QTc intervals during entire nights (meanQTc, lower 
panel) and mean QTc intervals during minutes with the highest values 
of the nights (maxQTc, upper panel) are shown. Significant differences 
(P < 0.05) between values at the higher altitudes versus values at 490 m, 
and between acetazolamide and placebo are indicated.
Figure 3—The effects of exposure to higher altitudes in patients using 
placebo (1860 and 2590 m, respectively) versus 490 m are illustrated 
by plotting median differences with 95% confidence interval (CI) of 
the corresponding mean QTc intervals during entire nights (meanQTc, 
panel A1), mean QTc intervals during minutes with the highest values of 
the nights (maxQTc, panel A2), and the QT dispersion (panel A3). The 
effects of acetazolamide vs. placebo at 1860 and 2590 m on meanQTc, 
maxQTc, and QT dispersion are illustrated in a similar way in panels B1-
B3. MeanQTc, maxQTc and QT dispersion were prolonged at the higher 
altitudes and acetazolamide prevented the altitude induced increase in 
meanQTc and in QT dispersion.
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that acetazolamide improves nocturnal arterial oxygen satura-
tion, AHI,16,17 and cerebral tissue oxygenation37 when used as 
the sole therapy or in combination with CPAP therapy. The 
current trial indicates that the improvement in arterial oxygen 
saturation by acetazolamide may have additional beneficial ef-
fects in OSA patients during altitude travel by preventing the 
prolongation of QTc and the associated risks (Table 2).
In summary, our study in patients with OSA who discon-
tinued CPAP therapy during a stay at 1860 m and 2590 m 
demonstrates that sustained and intermittent hypoxia at mod-
erate altitude leads to disturbed cardiac repolarization with a 
prolongation of the QTc interval and greater dispersion, sug-
gesting an increase in the risk of malignant arrhythmias. This 
may apply particularly to those suffering from coronary heart 
disease or using drugs that prolong QT duration such as cer-
tain antidepressants or macrolide antibiotics. Because acet-
azolamide improves arterial oxygen saturation and AHI and 
prevents prolongation of the meanQTc and QT dispersion, the 
drug might be beneficial for OSA patients who are unable to 
use CPAP therapy during altitude travel.
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